MedTrace Logo

Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety

NCT00944268 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2009-07-24

No results posted yet for this study

Summary

To evaluate the efficacy and tolerability of the combination use of Passiflora incarnata L, Crataegus oxyacantha and Salix alba L in mild and moderate anxiety.

Clinical study phase III, multicenter, prospective, open.

Patients will be included in sufficient quantity to achieve the minimum number of 124 evaluable patients.

Conditions

Interventions

DRUG

Passiflora, Crataegus e Salix

Comparison of different pharmaceutics forms of drug

Sponsors & Collaborators

  • Ativus Farmaceutica Ltda

    lead INDUSTRY

Principal Investigators

  • Elie Fiss · Faculdade de Medicina do ABC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2009-12-31
Completion
2010-01-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00944268 on ClinicalTrials.gov